Contrasting Moolec Science (MLEC) & Its Rivals

Moolec Science (NASDAQ:MLEC) is one of 499 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Moolec Science to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

Moolec Science has a beta of -0.54, indicating that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s competitors have a beta of 1.22, indicating that their average stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Moolec Science and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-6,886.12%	-100.15%	-26.34%

Analyst Recommendations

This is a summary of current recommendations and price targets for Moolec Science and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	1022	2959	7542	145	2.58

Moolec Science presently has a consensus price target of $6.00, suggesting a potential upside of 552.17%. As a group, “Biotechnology” companies have a potential upside of 25.35%. Given Moolec Science’s stronger consensus rating and higher possible upside, equities analysts clearly believe Moolec Science is more favorable than its competitors.

Valuation and Earnings

This table compares Moolec Science and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.60
Moolec Science Competitors	$1.55 billion	$43.90 million	122.06

Moolec Science’s competitors have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 34.1% of shares of all “Biotechnology” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by company insiders. Comparatively, 20.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Moolec Science competitors beat Moolec Science on 8 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.